Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Announces US$30 Million Loan Commitment Letter

GlobeNewswire April 11, 2018

Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease

GlobeNewswire March 28, 2018

Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial

GlobeNewswire March 19, 2018

Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire February 26, 2018

Resverlogix Highlights Key Accomplishments and 2018 Targets

GlobeNewswire February 8, 2018

Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial

GlobeNewswire January 11, 2018

Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement

GlobeNewswire January 8, 2018

Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis

GlobeNewswire December 14, 2017

Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders

GlobeNewswire December 12, 2017

Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1

GlobeNewswire December 12, 2017

Resverlogix Repays $68.8 Million Loan

GlobeNewswire December 6, 2017

Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink

GlobeNewswire December 4, 2017

Resverlogix Announces Participation in Upcoming Conferences

GlobeNewswire November 2, 2017

Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire November 1, 2017

Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.

GlobeNewswire October 24, 2017

IIROC Trade Resumption - RVX

Canada NewsWire October 13, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile October 13, 2017

IIROC Trading Halt - RVX

Canada NewsWire October 13, 2017

Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink

GlobeNewswire October 13, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile October 13, 2017